Evidence map›Paper›PMID 25771013›Full record

ArticleBiomaterials2015

Rapid determination of plasmonic nanoparticle agglomeration status in blood.

Samir V Jenkins, Haiou Qu, Thilak Mudalige, Taylor M Ingle, Rongrong Wang, Feng Wang, Paul C Howard, Jingyi Chen, Yongbin Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Samir V JenkinsNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, United States.
Haiou QuNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Arkansas Regional Laboratory, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Thilak MudaligeNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Arkansas Regional Laboratory, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Taylor M IngleNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Rongrong WangNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Hunan Province of Food and Drug Control, Changsha, Hunan 410001, China.
Feng WangDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, United States.
Paul C HowardNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
Jingyi ChenDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, United States.
Yongbin ZhangNCTR/ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, Jefferson, AR 72079, United States; Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States. Electronic address: Yongbin.Zhang@fda.hhs.gov.
National Center for Toxicological Research · USUnited States Food and Drug Administration · USUniversity of Arkansas at Fayetteville · US

Funding

Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
NIGMS NIH HHS P30 GM103450
6 · The paper itself

Abstract

Plasmonic nanomaterials as drug delivery or bio-imaging agents are typically introduced to biological systems through intravenous administration. However, the potential for agglomeration of nanoparticles in biological systems could dramatically affect their pharmacokinetic profile and toxic potential. Development of rapid screening methods to evaluate agglomeration is urgently needed to monitor the physical nature of nanoparticles as they are introduced into blood. Here, we establish novel methods using darkfield microscopy with hyperspectral detection (hsDFM), single particle inductively-coupled plasma mass spectrometry (spICP-MS), and confocal Raman microscopy (cRM) to discriminate gold nanoparticles (AuNPs) and their agglomerates in blood. Rich information about nanoparticle agglomeration in situ is provided by hsDFM monitoring of the plasmon resonance of primary nanoparticles and their agglomerates in whole blood; cRM is an effective complement to hsDFM to detect AuNP agglomerates in minimally manipulated samples. The AuNPs and the particle agglomerates were further distinguished in blood for the first time by quantification of particle mass using spICP-MS with excellent sensitivity and specificity. Furthermore, the agglomeration status of synthesized and commercial NPs incubated in blood was successfully assessed using the developed methods. Together, these complementary methods enable rapid determination of the agglomeration status of plasmonic nanomaterials in biological systems, specifically blood.

Indexed as

AnimalsBloodCitratesMetal NanoparticlesMicroscopyRats, Inbred F344Scattering, RadiationSpectrophotometry, AtomicSpectrum Analysis, RamanCitratesBloodDarkfield microscopyGoldNanoparticlesSilverSingle particle ICP-MS

Identifiers

PMID25771013
PMCPMC4369056
OpenAlexW1985488244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.